1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Targeted Therapies in Asthma - 2017

Targeted Therapies in Asthma - 2017

  • February 2017
  • ID: 3612602
  • Format: PDF
  • By Firstword Pharma


Table of Contents


As new targeted asthma therapies emerge, is time running out for Xolair?

Xolair’s unique position in the targeted asthma treatment market is under threat. Teva’s Cinqair and GSK’s Nucala have emerged as significant threats to Xolair’s dominance. What can Roche and Novartis do to stop the rot? Will clinical data save the day, or will commercial tactics be the critical difference in a rapidly evolving market? Learn how key opinion leaders (KOLs) see the market evolving, and how they expect developers to differentiate their pipeline asthma antibodies in KOL Insight: Targeted Therapies in Asthma. Twelve US and European KOLs give their insight on three marketed products and 8 pipeline programmes.

KOLs also provide their candid views on the potential for Xolair biosimilars, and what it would take for these products to gain traction in the targeted asthma treatment market.

Top takeaways
- Will Xolair (omalizumab) remain the treatment of choice for allergic asthma patients'Xolair may remain first-line-therapy for allergic asthma patients with elevated serum IgE levels, but for some patients other treatment options might be a better strategy. Find out what they are.
- How important is Xolair’s paediatric label extension, and will it support future clinical differentiation? KOLs provide their insights on Xolair’s expanded labelling to include paediatric patients, but will it mean anything clinically? And do KOLs expect long-term Xolair therapy to have any disease-modifying activity in this patient cohort?
- Do current and emerging anti-IL5 mAbs represent a clinically significant advancement in the treatment of severe asthma? Nucala (mepolizumab) represents the first mAb to receive approval for severe asthma in over a decade. Other anti-IL5 mAbs are in development (e.g. AstraZeneca’s benralizumab). But will targeting this pathway improve clinical outcomes in severe asthma? Find out what KOLs think.
- What pipeline programmes are KOLs becoming particularly excited about? Are next-generation anti-IL5 mAbs set to change the course of the severe asthma treatment market, or will it be Regeneron/Sanofi’s anti-IL-4/IL-13 mAb, dupilumab? Find out what KOLs are monitoring, and what they hope late-stage clinical studies will tell them.
- Biosimilar versions of omalizumab are coming, but what impact will they have on the market? Xolair biosimilars are in development and could come to certain markets by 2018. What do KOLs think about these products, and how important will clinical studies proving equivalent safety and efficacy be in driving uptake? Moreover, how can Xolair biosimilars help cut the cost of treating severe asthma, an issue which many KOLs believe is limiting patient access and negatively impacting patient care.
- What’s the future of biomarkers in identifying responsive patients? With precision medicine becoming a critical enabler of product use in a number of disease areas, find out what KOLs think about the use of biomarkers in defining eligible patient populations in the severe asthma market and how this could help eliminate “trial and error” approaches to treatment decisions.

“The concept of biosimilars is going to be a big challenge. They don’t have a lot in the peer review literature to really give us a sense of the efficacy that they’re going to provide. I think it’s hard to make a definitive statement around those.” US Key Opinion Leader

“There will be patients that are treated better with Xolair, we will have patients that are treated only with Nucala, but we will have patients that are eligible for both. We switch uncontrolled Xolair patients to Nucala, and some patients have to switch back to Xolair because Nucala, despite their eosinophilia of 300 or 400, is not as effective as Xolair, and vice versa.” European Key Opinion Leader

KOLs Interviewed
KOLs from North America
- Dr Leonard B. Bacharier MD, Professor of Pediatrics and Clinical Director, Division of Allergy, Immunology and Pulmonary Medicine at Washington University School of Medicine in St. Louis, USA
- Dr Mark J. Fitzgerald MD, Director at the Centre for Heart and Lung Health at Vancouver Coastal Health Research Institute, Vancouver, Canada
- Dr Gailen D. Marshall, MD, PhD, Professor of Medicine and Pediatrics, Director, Division of Clinical Immunology and Allergy, The University of Mississippi Medical Center MS, USA
- Dr Reynold A. Panettieri, MD, Professor of Medicine, Perelman School of Medicine, University of Pennsylvania PA, USA
- Dr Mike E. Wechsler MD, MMSc, Associate Physician, Brigham and Women's Hospital, Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA
- Anonymous US KOL, internal medicine expert specialising in asthma

KOLs from Europe
- Professor Arnaud Bourdin, MD, Head of General Pneumology, CHU de Montpellier, Montpellier, France
- Professor Andy Wardlaw, MD, Head of Department and Professor of Respiratory Medicine, Glenfield Hospital, Leicester, UK
- Professor Kian Fan Chung, MD, Professor of Respiratory Medicine, Royal Brompton Hospital, London, UK
- Anonymous French KOL, Professor at leading university in France
- Anonymous German KOL, Professor at a leading university in Germany
- Anonymous German KOL, Professor at a leading university in Germany

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Eosinophilic Esophagitis - Pipeline Review, H2 2019

Eosinophilic Esophagitis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Eosinophilic Esophagitis - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2019, provides an overview of the ...

Chronic Urticaria Or Hives - Pipeline Review, H2 2019

Chronic Urticaria Or Hives - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Chronic Urticaria Or Hives - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2019, provides an overview of ...

Allergic Asthma Global Clinical Trials Review, H2, 2019

Allergic Asthma Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Allergic Asthma Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Allergic Asthma Global Clinical Trials Review, H2, 2019" provides an overview of Allergic Asthma clinical trials ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on